{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T22:58:16Z","timestamp":1791068296264,"version":"4.1.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T00:00:00Z","timestamp":1277942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T00:00:00Z","timestamp":1277942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1124\/jpet.110.167346","type":"journal-article","created":{"date-parts":[[2010,4,19]],"date-time":"2010-04-19T23:21:50Z","timestamp":1271719310000},"page":"171-181","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":397,"title":["Pharmacological Profile of Lurasidone, a Novel Antipsychotic Agent with Potent 5-Hydroxytryptamine 7 (5-HT7) and 5-HT1A Receptor Activity"],"prefix":"10.1016","volume":"334","author":[{"given":"Tadashi","family":"Ishibashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Horisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumiko","family":"Tokuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeo","family":"Ishiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Ogasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rie","family":"Tagashira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoko","family":"Toma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitomi","family":"Oki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiko","family":"Tanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikutaro","family":"Saji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiro","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsutaka","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.110.167346_bib1","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1001\/archpsyc.1990.01810190015002","article-title":"Positive and negative symptoms in schizophrenia. A critical reappraisal","volume":"47","author":"Andreasen","year":"1990","journal-title":"Arch Gen Psychiatry"},{"key":"10.1124\/jpet.110.167346_bib2","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1600-0773.1982.tb01032.x","article-title":"Pharmacological specificity of conditioned avoidance response inhibition in rats: inhibition by neuroleptics and correlation to dopamine receptor blockade","volume":"51","author":"Arnt","year":"1982","journal-title":"Acta Pharmacol Toxicol (Copenh)"},{"key":"10.1124\/jpet.110.167346_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00213-006-0577-y","article-title":"The drug-induced helplessness test: an animal assay for assessing behavioral despair in response to neuroleptic treatment","volume":"190","author":"Ballard","year":"2007","journal-title":"Psychopharmacology"},{"issue":"Suppl 3","key":"10.1124\/jpet.110.167346_bib4","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1097\/00004850-199803003-00009","article-title":"Novel antipsychotics, extrapyramidal side effects and tardive dyskinesia","volume":"13","author":"Barnes","year":"1998","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1124\/jpet.110.167346_bib5","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/00002826-199012000-00003","article-title":"5-HT2 antagonist ritanserin in neuroleptic-induced parkinsonism: a double-blind comparison with orphenadrine and placebo","volume":"13","author":"Bersani","year":"1990","journal-title":"Clin Neuropharmacol"},{"key":"10.1124\/jpet.110.167346_bib6","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0306-4522(99)00428-5","article-title":"Overexpression of \u03b12C-adrenoecptors impairs water maze navigation","volume":"95","author":"Bj\u00f6rklund","year":"2000","journal-title":"Neuroscience"},{"key":"10.1124\/jpet.110.167346_bib7","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00213-009-1583-7","article-title":"Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice","volume":"206","author":"Bourin","year":"2009","journal-title":"Psychopharmacology"},{"key":"10.1124\/jpet.110.167346_bib8","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1192\/S0007125000298292","article-title":"Extrapyramidal syndromes and new antipsychotic drugs: findings in patients and non-human primate models","volume":"29","author":"Casey","year":"1996","journal-title":"Br J Psychiatry Suppl"},{"key":"10.1124\/jpet.110.167346_bib9","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1111\/j.1471-4159.1979.tb02276.x","article-title":"Heterogeneity of histamine H1-receptors: species variations in [3H]mepyramine binding of brain membranes","volume":"32","author":"Chang","year":"1979","journal-title":"J Neurochem"},{"key":"10.1124\/jpet.110.167346_bib10","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/BF00187254","article-title":"The paw test: a behavioural paradigm for differentiating between classical and atypical neuroleptic drugs","volume":"93","author":"Ellenbroek","year":"1987","journal-title":"Psychopharmacology"},{"key":"10.1124\/jpet.110.167346_bib11","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.bbr.2007.08.012","article-title":"Lurasidone reverses MK-801-induced impairment of learning and memory in the Morris water maze and radial-arm maze test in rats","volume":"186","author":"Enomoto","year":"2008","journal-title":"Behav Brain Res"},{"key":"10.1124\/jpet.110.167346_bib12","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.bbr.2007.12.020","article-title":"Effect of 5-HT7 antagonist SB-269970 in the modulation of working and reference memory in the rat","volume":"195","author":"Gasbarri","year":"2008","journal-title":"Behav Brain Res"},{"key":"10.1124\/jpet.110.167346_bib13","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1177\/0269881105058378","article-title":"Weight change with atypical antipsychotics in the treatment of schizophrenia","volume":"19","author":"Haddad","year":"2005","journal-title":"J Psychopharmacol"},{"key":"10.1124\/jpet.110.167346_bib14","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.schres.2003.07.009","article-title":"Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia","volume":"66","author":"Harvey","year":"2004","journal-title":"Schizophr Res"},{"key":"10.1124\/jpet.110.167346_bib15","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.tips.2004.07.002","article-title":"Functional, molecular and pharmacological advances in 5-HT7 receptor research","volume":"25","author":"Hedlund","year":"2004","journal-title":"Trends Pharmacol Sci"},{"key":"10.1124\/jpet.110.167346_bib16","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.biopsych.2005.05.012","article-title":"5-HT7 receptor inhibition and inactivation induce antidepressantlike behavior and sleep pattern","volume":"58","author":"Hedlund","year":"2005","journal-title":"Biol Psychiatry"},{"key":"10.1124\/jpet.110.167346_bib17","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1254\/jjp.53.321","article-title":"Pharmacological actions of SM-9018, a new neuroleptic drug with both potent 5-hydroxytryptamine2 and dopamine2 antagonistic actions","volume":"53","author":"Hirose","year":"1990","journal-title":"Jpn J Pharmacol"},{"key":"10.1124\/jpet.110.167346_bib18","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejphar.2007.06.058","article-title":"Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test","volume":"572","author":"Ishiyama","year":"2007","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.110.167346_bib19","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1254\/jjp.54.478","article-title":"Binding profile of SM-9018, a novel antipsychotic candidate","volume":"54","author":"Kato","year":"1990","journal-title":"Jpn J Pharmacol"},{"key":"10.1124\/jpet.110.167346_bib20","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0163-7258(97)00004-1","article-title":"The olfactory bulbectomized rat as a model of depression: an update","volume":"74","author":"Kelly","year":"1997","journal-title":"Pharmacol Ther"},{"key":"10.1124\/jpet.110.167346_bib21","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/sj.npp.1300027","article-title":"H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs","volume":"28","author":"Kroeze","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/jpet.110.167346_bib22","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet"},{"key":"10.1124\/jpet.110.167346_bib23","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1192\/S0007125000292544","article-title":"Understanding the mechanisms of action of atypical antipsychotic drugs: a review of compounds in use and development","volume":"22","author":"Lieberman","year":"1993","journal-title":"Br J Psychiatry Suppl"},{"key":"10.1124\/jpet.110.167346_bib24","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0022-3565(25)03549-9","article-title":"A simplified method of evaluating dose-effect experiments","volume":"96","author":"Litchfield","year":"1949","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.110.167346_bib25","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/S0006-3223(99)00255-3","article-title":"Treatment of schizophrenia and spectrum disorders: pharmacotherapy, psychosocial treatments, and neurotransmitter interactions","volume":"46","author":"Meltzer","year":"1999","journal-title":"Biol Psychiatry"},{"key":"10.1124\/jpet.110.167346_bib26","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.pnpbp.2003.09.010","article-title":"Serotonin receptors: their key role in drugs to treat schizophrenia","volume":"27","author":"Meltzer","year":"2003","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1124\/jpet.110.167346_bib27","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.bbr.2004.04.026","article-title":"Effects of the 5-HT7 receptor antagonists SB-269970 and DR 4004 in autoshaping Pavlovian\/instrumental learning task","volume":"155","author":"Meneses","year":"2004","journal-title":"Behav Brain Res"},{"key":"10.1124\/jpet.110.167346_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1517\/13543780903286388","article-title":"Lurasidone: a new drug in development for schizophrenia","volume":"18","author":"Meyer","year":"2009","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1124\/jpet.110.167346_bib29","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S0022-3565(24)38982-7","article-title":"Improving the treatment of schizophrenia: focus on serotonin (5-HT)1A receptors","volume":"295","author":"Millan","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.110.167346_bib30","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0022-3565(25)10792-1","article-title":"The behavioral pharmacology of olanzapine, a novel \u201catypical\u201d antipsychotic agent","volume":"262","author":"Moore","year":"1992","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.110.167346_bib31","doi-asserted-by":"crossref","first-page":"829","DOI":"10.4088\/JCP.08m04905","article-title":"Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial","volume":"70","author":"Nakamura","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"10.1124\/jpet.110.167346_bib32","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0091-3057(94)90451-0","article-title":"Evaluation of bradykinesia induction by SM-9018, a novel 5-HT2 and D2 receptor antagonist, using the mouse pole test","volume":"49","author":"Ohno","year":"1994","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1124\/jpet.110.167346_bib33","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/1359786806066040","article-title":"The 5-HT2C receptor and antipsychotic-induced weight gain \u2013 mechanisms and genetics","volume":"20","author":"Reynolds","year":"2006","journal-title":"J Psychopharmacol"},{"key":"10.1124\/jpet.110.167346_bib34","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0893-133X(95)00239-A","article-title":"1192U90 in animal tests that predict antipsychotic efficacy, anxiolysis, and expyramidal side effects","volume":"15","author":"Rigdon","year":"1996","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/jpet.110.167346_bib35","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1111\/j.1460-9568.2004.03288.x","article-title":"Mice lacking 5-HT receptors show specific impairments in contextual learning","volume":"19","author":"Roberts","year":"2004","journal-title":"Eur J Neurosci"},{"key":"10.1124\/jpet.110.167346_bib36","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.neuropharm.2004.01.010","article-title":"GABAergic modulation of 5-HT7 receptor-mediated 5-HT efflux in the guinea-pig dorsal raphe nucleus","volume":"46","author":"Roberts","year":"2004","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.110.167346_bib37","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S0091-3057(98)00068-9","article-title":"Anxiolytic-like effects of perospirone, a novel serotonin-2 and dopamine-2 antagonist (SDA)-type antipsychotic agent","volume":"60","author":"Sakamoto","year":"1998","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1124\/jpet.110.167346_bib38","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/sj.bjp.0707005","article-title":"Pharmacological characterization and CNS effects of a novel highly selective \u03b12C-adrenoceptors antagonist JP-1302","volume":"150","author":"Sallinen","year":"2007","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.110.167346_bib39","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1126\/science.1083328","article-title":"Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants","volume":"301","author":"Santarelli","year":"2003","journal-title":"Science"},{"key":"10.1124\/jpet.110.167346_bib40","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbr.2009.03.011","article-title":"The 5-HT7 receptor is involved in allocentric spatial memory information processing","volume":"202","author":"Sarkisyan","year":"2009","journal-title":"Behav Brain Res"},{"key":"10.1124\/jpet.110.167346_bib41","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0021-5198(19)43370-2","article-title":"Pharmacological properties of SM-3997: a new anxioselective anxiolytic candidate","volume":"45","author":"Shimizu","year":"1987","journal-title":"Jpn J Pharmacol"},{"key":"10.1124\/jpet.110.167346_bib42","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/IOP.0b013e3181462a2e","article-title":"Adrenergic receptors in the ptotic human eyelid: correlation with phenylephrine testing and surgical success in ptosis repair","volume":"23","author":"Skibell","year":"2007","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"10.1124\/jpet.110.167346_bib43","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/0091-3057(89)90079-8","article-title":"Effect of the putative anxiolytic SM-3997 on central monoaminergic systems","volume":"32","author":"Tatsuno","year":"1989","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1124\/jpet.110.167346_bib44","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1124\/jpet.106.106047","article-title":"Time-dependent cognitive deficits associated with first and second generation antipsychotics: cholinergic dysregulation as a potential mechanism","volume":"320","author":"Terry","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.110.167346_bib45","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1476-5381.1995.tb16327.x","article-title":"Characterization and distribution of putative 5-ht7 receptors in guinea-pig brain","volume":"115","author":"To","year":"1995","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.110.167346_bib46","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0014-2999(97)01521-5","article-title":"[3H]RS79948-197 binding to human, rat, guinea pig and pig \u03b12A-, \u03b12B- and \u03b12C-adrenoceptors. Comparison with MK912, RX821002, rauwolscine and yohimbine","volume":"343","author":"Uhl\u00e9n","year":"1998","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.110.167346_bib47","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.neuropharm.2006.04.017","article-title":"Effect of the selective 5-HT7 receptor antagonist SB 269970 in animal models of anxiety and depression","volume":"51","author":"Weso\u0142owska","year":"2006","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.110.167346_bib48","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1163\/1569391041501933","article-title":"Effects of tandospirone, a novel anxiolytic agent, on human 5-HT1A receptors expressed in Chinese hamster ovary cells (CHO cells)","volume":"18","author":"Yabuuchi","year":"2004","journal-title":"Biogenic Amines"},{"key":"10.1124\/jpet.110.167346_bib49","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1073\/pnas.71.5.1725","article-title":"Muscarinic cholinergic binding in rat brain","volume":"71","author":"Yamamura","year":"1974","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524458722?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524458722?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.110.167346","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T21:14:08Z","timestamp":1739999648000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524458722"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["S0022356524458722"],"URL":"https:\/\/doi.org\/10.1124\/jpet.110.167346","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2010,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological Profile of Lurasidone, a Novel Antipsychotic Agent with Potent 5-Hydroxytryptamine 7 (5-HT7) and 5-HT1A Receptor Activity","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.110.167346","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2010 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}